-
1
-
-
79958780802
-
Perspective: Test and treat this silent killer
-
B. R. Edlin, "Perspective: Test and treat this silent killer, " Nature, vol. 474, no. 7350, pp. S18-S19, 2011.
-
(2011)
Nature
, vol.474
, Issue.7350
, pp. S18-S19
-
-
Edlin, B.R.1
-
2
-
-
84901838719
-
-
Center for Disease Control and Prevention (CDC)
-
Center for Disease Control and Prevention (CDC), "Surveillance for Viral Hepatitis-United States, " 2013, http://www. cdc. gov/hepatitis/statistics/2013surveillance/commentary. htm#hepatitisC.
-
(2013)
Surveillance for Viral Hepatitis-United States
-
-
-
3
-
-
84914150658
-
Global epidemiology and genotype distribution of the hepatitis C virus infection
-
E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi, "Global epidemiology and genotype distribution of the hepatitis C virus infection, " Journal of Hepatology, vol. 61, no. 1, pp. S45-S57, 2014.
-
(2014)
Journal of Hepatology
, vol.61
, Issue.1
, pp. S45-S57
-
-
Gower, E.1
Estes, C.2
Blach, S.3
Razavi-Shearer, K.4
Razavi, H.5
-
4
-
-
84903643207
-
Hepatitis C worldwide and in Brazil: Silent epidemic-data on disease including incidence, transmission, prevention, and treatment
-
I. F. Kretzer, A. do Livramento, J. da Cunha et al., "Hepatitis C worldwide and in Brazil: silent epidemic-data on disease including incidence, transmission, prevention, and treatment, " The Scientific World Journal, vol. 2014, Article ID 827849, 10 pages, 2014.
-
(2014)
The Scientific World Journal
, vol.2014
-
-
Kretzer, I.F.1
Do Livramento, A.2
Da Cunha, J.3
-
5
-
-
84894634227
-
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
-
J. Grebely, K. Page, R. Sacks-Davis et al., "The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection, " Hepatology, vol. 59, no. 1, pp. 109-120, 2014.
-
(2014)
Hepatology
, vol.59
, Issue.1
, pp. 109-120
-
-
Grebely, J.1
Page, K.2
Sacks-Davis, R.3
-
6
-
-
49649118223
-
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression
-
H.-H. Thein, Q. Yi, G. J. Dore, and M. D. Krahn, "Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression, " Hepatology, vol. 48, no. 2, pp. 418-431, 2008.
-
(2008)
Hepatology
, vol.48
, Issue.2
, pp. 418-431
-
-
Thein, H.-H.1
Yi, Q.2
Dore, G.J.3
Krahn, M.D.4
-
7
-
-
84871036375
-
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010
-
R. Lozano, M. Naghavi, K. Foreman et al., "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010, " The Lancet, vol. 380, no. 9859, pp. 2095-2128, 2012.
-
(2012)
The Lancet
, vol.380
, Issue.9859
, pp. 2095-2128
-
-
Lozano, R.1
Naghavi, M.2
Foreman, K.3
-
8
-
-
84880301028
-
Current progress in development of hepatitis C virus vaccines
-
T. J. Liang, "Current progress in development of hepatitis C virus vaccines, " Nature Medicine, vol. 19, no. 7, pp. 869-878, 2013.
-
(2013)
Nature Medicine
, vol.19
, Issue.7
, pp. 869-878
-
-
Liang, T.J.1
-
9
-
-
84921484801
-
Progress towards a hepatitis C virus vaccine
-
L. Man John Law, A. Landi, W. C. Magee, D. Lorne Tyrrell, and M. Houghton, "Progress towards a hepatitis C virus vaccine, " Emerging Microbes and Infections, vol. 2, article e79, 2013.
-
(2013)
Emerging Microbes and Infections
, vol.2
-
-
Man John Law, L.1
Landi, A.2
Magee, W.C.3
Lorne Tyrrell, D.4
Houghton, M.5
-
10
-
-
84952837127
-
Universal screening for chronic hepatitis C virus
-
M. L. Shiffman, "Universal screening for chronic hepatitis C virus, " Liver International, vol. 36, no. S1, pp. 62-66, 2016.
-
(2016)
Liver International
, vol.36
, Issue.S1
, pp. 62-66
-
-
Shiffman, M.L.1
-
11
-
-
84986290313
-
2014 French guidelines for hepatitis B and C screening. A combined targeted andmass testing strategy of chronic viruses namely HBV, HCV and HIV
-
J. Bottero, C. Brouard, F. Roudot-Thoraval et al., "2014 French guidelines for hepatitis B and C screening. A combined targeted andmass testing strategy of chronic viruses namely HBV, HCV and HIV, " Liver International, vol. 36, no. 10, pp. 1442-1449, 2016.
-
(2016)
Liver International
, vol.36
, Issue.10
, pp. 1442-1449
-
-
Bottero, J.1
Brouard, C.2
Roudot-Thoraval, F.3
-
12
-
-
84963960484
-
HIV and hepatitis testing: Global progress, challenges, and future directions
-
P. Easterbrook, C. Johnson, C. Figueroa, and R. Baggaley, "HIV and hepatitis testing: global progress, challenges, and future directions, " AIDS Reviews, vol. 18, no. 1, pp. 3-14, 2016.
-
(2016)
AIDS Reviews
, vol.18
, Issue.1
, pp. 3-14
-
-
Easterbrook, P.1
Johnson, C.2
Figueroa, C.3
Baggaley, R.4
-
13
-
-
84861575412
-
Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008
-
M. M. Denniston, R. M. Klevens, G. M. McQuillan, and R. B. Jiles, "Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008, " Hepatology, vol. 55, no. 6, pp. 1652-1661, 2012.
-
(2012)
Hepatology
, vol.55
, Issue.6
, pp. 1652-1661
-
-
Denniston, M.M.1
Klevens, R.M.2
McQuillan, G.M.3
Jiles, R.B.4
-
14
-
-
0004016899
-
-
World Health Organization, Fact Sheet 164, World Health Organization, Geneva, Switzerland
-
World Health Organization, "Hepatitis C, " Fact Sheet 164, World Health Organization, Geneva, Switzerland, 2015, http:// www. who. int/mediacentre/factsheets/fs164/en/.
-
(2015)
Hepatitis C
-
-
-
17
-
-
84867286818
-
Laboratory diagnostics for hepatitis C virus infection
-
S. Kamili, J. Drobeniuc, A. C. Araujo, and T. M. Hayden, "Laboratory diagnostics for hepatitis C virus infection, " Clinical Infectious Diseases, vol. 55, supplement 1, pp. S43-S48, 2012.
-
(2012)
Clinical Infectious Diseases
, vol.55
, pp. S43-S48
-
-
Kamili, S.1
Drobeniuc, J.2
Araujo, A.C.3
Hayden, T.M.4
-
18
-
-
84981347760
-
Update on hepatitis B and C virus diagnosis
-
L. M. Villar, H. M. Cruz, C. S. Barbosa Bezerra Jr., M. M. Portilho, and P. Scalioni Lde, "Update on hepatitis B and C virus diagnosis, " World Journal of Virology, vol. 4, no. 4, pp. 323-342, 2015.
-
(2015)
World Journal of Virology
, vol.4
, Issue.4
, pp. 323-342
-
-
Villar, L.M.1
Cruz, H.M.2
Barbosa Bezerra, C.S.3
Portilho, M.M.4
Scalioni Lde, P.5
-
19
-
-
84930398412
-
Hepatitis C virus: Virology, diagnosis and treatment
-
H. C. Li and S. Y. Lo, "Hepatitis C virus: virology, diagnosis and treatment, " World Journal of Hepatology, vol. 7, no. 10, pp. 1377-1389, 2015.
-
(2015)
World Journal of Hepatology
, vol.7
, Issue.10
, pp. 1377-1389
-
-
Li, H.C.1
Lo, S.Y.2
-
20
-
-
84912098460
-
Diagnostic tests for hepatitis C: Recent trends in electrochemical immunosensor and genosensor analysis
-
C. V. Uliana, C. S. Riccardi, andH. Yamanaka, "Diagnostic tests for hepatitis C: recent trends in electrochemical immunosensor and genosensor analysis, " World Journal of Gastroenterology, vol. 20, no. 42, pp. 15476-15491, 2014.
-
(2014)
World Journal of Gastroenterology
, vol.20
, Issue.42
, pp. 15476-15491
-
-
Uliana, C.V.1
Riccardi, C.S.2
Yamanaka, H.3
-
21
-
-
33646270395
-
Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease
-
S. Chevaliez and J.-M. Pawlotsky, "Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease, " International Journal of Medical Sciences, vol. 3, no. 2, pp. 35-40, 2006.
-
(2006)
International Journal of Medical Sciences
, vol.3
, Issue.2
, pp. 35-40
-
-
Chevaliez, S.1
Pawlotsky, J.-M.2
-
22
-
-
79955681183
-
Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity
-
F. Alborino, A. Burighel, F.-W. Tiller et al., "Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity, " Medical Microbiology and Immunology, vol. 200, no. 2, pp. 77-83, 2011.
-
(2011)
Medical Microbiology and Immunology
, vol.200
, Issue.2
, pp. 77-83
-
-
Alborino, F.1
Burighel, A.2
Tiller, F.-W.3
-
23
-
-
0035076670
-
Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature
-
C. Colin, D. Lanoir, S. Touzet, L. Meyaud-Kraemer, F. Bailly, and C. Trepo, "Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature, " Journal of Viral Hepatitis, vol. 8, no. 2, pp. 87-95, 2001.
-
(2001)
Journal of Viral Hepatitis
, vol.8
, Issue.2
, pp. 87-95
-
-
Colin, C.1
Lanoir, D.2
Touzet, S.3
Meyaud-Kraemer, L.4
Bailly, F.5
Trepo, C.6
-
24
-
-
0028795676
-
Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA
-
J. M. Barrera, B. Francis, G. Ercilla et al., "Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA, " Vox Sanguinis, vol. 68, no. 1, pp. 15-18, 1995.
-
(1995)
Vox Sanguinis
, vol.68
, Issue.1
, pp. 15-18
-
-
Barrera, J.M.1
Francis, B.2
Ercilla, G.3
-
25
-
-
84861334032
-
NASPGHAN Practice guidelines: Diagnosis and management of hepatitis c infection in infants, children, and adolescents
-
C. L. Mack, R. P. Gonzalez-Peralta, N. Gupta et al., "NASPGHAN Practice guidelines: diagnosis and management of hepatitis c infection in infants, children, and adolescents, " Journal of Pediatric Gastroenterology and Nutrition, vol. 54, no. 6, pp. 838-855, 2012.
-
(2012)
Journal of Pediatric Gastroenterology and Nutrition
, vol.54
, Issue.6
, pp. 838-855
-
-
Mack, C.L.1
Gonzalez-Peralta, R.P.2
Gupta, N.3
-
26
-
-
80055096809
-
HepatitisCvirus core antigen: Analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay
-
M. C. Medici, G. Furlini, A. Rodella et al., "HepatitisCvirus core antigen: Analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay, " Journal of Clinical Virology, vol. 51, no. 4, pp. 264-269, 2011.
-
(2011)
Journal of Clinical Virology
, vol.51
, Issue.4
, pp. 264-269
-
-
Medici, M.C.1
Furlini, G.2
Rodella, A.3
-
27
-
-
84924935494
-
Hepatitis C core antigen testing: A reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection
-
F. V. Cresswell, M. Fisher, D. J. Hughes, S. G. Shaw, G. Homer, and M. O. Hassan-Ibrahim, "Hepatitis C core antigen testing: A reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection, " Clinical Infectious Diseases, vol. 60, no. 2, pp. 263-266, 2015.
-
(2015)
Clinical Infectious Diseases
, vol.60
, Issue.2
, pp. 263-266
-
-
Cresswell, F.V.1
Fisher, M.2
Hughes, D.J.3
Shaw, S.G.4
Homer, G.5
Hassan-Ibrahim, M.O.6
-
28
-
-
84870405295
-
Hepatitis C virus testing of persons born during 1945-1965: Recommendations from the centers for disease control and prevention
-
B. D. Smith, R. L. Morgan, G. A. Beckett, Y. Falck-Ytter, D. Holtzman, and J. W. Ward, "Hepatitis C virus testing of persons born during 1945-1965: recommendations from the centers for disease control and prevention, " Annals of Internal Medicine, vol. 157, no. 11, pp. 817-822, 2012.
-
(2012)
Annals of Internal Medicine
, vol.157
, Issue.11
, pp. 817-822
-
-
Smith, B.D.1
Morgan, R.L.2
Beckett, G.A.3
Falck-Ytter, Y.4
Holtzman, D.5
Ward, J.W.6
-
30
-
-
84868333689
-
Accuracy of rapid and point-of-care screening tests for hepatitis C: A systematic review and meta-analysis
-
S. Shivkumar, R. Peeling, Y. Jafari, L. Joseph, and N. Pant Pai, "Accuracy of rapid and point-of-care screening tests for hepatitis C: A systematic review and meta-analysis, " Annals of Internal Medicine, vol. 157, no. 8, pp. 558-566, 2012.
-
(2012)
Annals of Internal Medicine
, vol.157
, Issue.8
, pp. 558-566
-
-
Shivkumar, S.1
Peeling, R.2
Jafari, Y.3
Joseph, L.4
Pant Pai, N.5
-
31
-
-
84902164210
-
Performance of rapid hepatitis C virus antibody assays among high-and lowrisk populations
-
L. D. P. Scalioni, H. M. Cruz, V. S. de Paula et al., "Performance of rapid hepatitis C virus antibody assays among high-and lowrisk populations, " Journal of Clinical Virology, vol. 60, no. 3, pp. 200-205, 2014.
-
(2014)
Journal of Clinical Virology
, vol.60
, Issue.3
, pp. 200-205
-
-
Scalioni, L.D.P.1
Cruz, H.M.2
De Paula, V.S.3
-
32
-
-
84926290284
-
Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: A systematic review and meta-analysis
-
M. S. Khuroo, N. S. Khuroo, and M. S. Khuroo, "Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: A systematic review and meta-analysis, " PLoS ONE, vol. 10, no. 3, Article ID e0121450, 2015.
-
(2015)
PLoS ONE
, vol.10
, Issue.3
-
-
Khuroo, M.S.1
Khuroo, N.S.2
Khuroo, M.S.3
-
33
-
-
84938952874
-
-
National Institute for Health and Clinical Excellence (NICE), NICE, London, UK, 2012
-
National Institute for Health and Clinical Excellence (NICE), Hepatitis B and C: Ways to Promote and Offer Testing to People at Increased Risk of Infection, NICE, London, UK, 2012, http://www. nice. org. uk/nicemedia/live/14003/61863/61863. pdf.
-
Hepatitis B and C: Ways to Promote and Offer Testing to People at Increased Risk of Infection
-
-
-
34
-
-
84867288022
-
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
-
Centers for Disease Control and Prevention (CDC)
-
Centers for Disease Control and Prevention (CDC), "Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965, " Morbidity and Mortality Weekly Report (MMWR), vol. 61, no. RR04, pp. 1-32, 2012, http://www. cdc. gov/mmwr/pdf/rr/rr6104. pdf.
-
(2012)
Morbidity and Mortality Weekly Report (MMWR)
, vol.61
, Issue.RR04
, pp. 1-32
-
-
-
35
-
-
84939653819
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
-
AASLD/IDSA HCV Guidance Panel
-
AASLD/IDSA HCV Guidance Panel, "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, " Hepatology, vol. 62, no. 3, pp. 932-954, 2015.
-
(2015)
Hepatology
, vol.62
, Issue.3
, pp. 932-954
-
-
-
36
-
-
84867288022
-
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
-
B. D. Smith, R. L. Morgan, G. A. Beckett et al., "Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965, " MMWR Recommendations and Reports, vol. 61, no. 4, pp. 1-32, 2012.
-
(2012)
MMWR Recommendations and Reports
, vol.61
, Issue.4
, pp. 1-32
-
-
Smith, B.D.1
Morgan, R.L.2
Beckett, G.A.3
-
37
-
-
84881147288
-
Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U. S. Preventive Services Task Force recommendation statement
-
V. A. Moyer, "Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U. S. Preventive Services Task Force recommendation statement, " Annals of Internal Medicine, vol. 159, no. 3, pp. 210-218, 2013.
-
(2013)
Annals of Internal Medicine
, vol.159
, Issue.3
, pp. 210-218
-
-
Moyer, V.A.1
-
38
-
-
0035726250
-
Management of hepatitis C patients by primary care physicians in the USA: Results of a national survey
-
T. M. Shehab, S. S. Sonnad, and A. S. F. Lok, "Management of hepatitis C patients by primary care physicians in the USA: results of a national survey, " Journal of Viral Hepatitis, vol. 8, no. 5, pp. 377-383, 2001.
-
(2001)
Journal of Viral Hepatitis
, vol.8
, Issue.5
, pp. 377-383
-
-
Shehab, T.M.1
Sonnad, S.S.2
Lok, A.S.F.3
-
39
-
-
0037345681
-
Identification and management of hepatitis C patients in primary care clinics
-
T. M. Shehab, M. Orrego, R. Chunduri, and A. S. F. Lok, "Identification and management of hepatitis C patients in primary care clinics, "The American Journal of Gastroenterology, vol. 98, no. 3, pp. 639-644, 2003.
-
(2003)
The American Journal of Gastroenterology
, vol.98
, Issue.3
, pp. 639-644
-
-
Shehab, T.M.1
Orrego, M.2
Chunduri, R.3
Lok, A.S.F.4
-
40
-
-
84880172886
-
Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010
-
R. Mahajan, S. J. Liu, R. M. Klevens, and S. D. Holmberg, "Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010, " American Journal of Public Health, vol. 103, no. 8, pp. 1445-1449, 2013.
-
(2013)
American Journal of Public Health
, vol.103
, Issue.8
, pp. 1445-1449
-
-
Mahajan, R.1
Liu, S.J.2
Klevens, R.M.3
Holmberg, S.D.4
-
41
-
-
84876675062
-
Electronic messages increase hepatitis B screening in at-risk Asian American patients: A randomized, controlled trial
-
L. Hsu, C. L. Bowlus, S. L. Stewart et al., "Electronic messages increase hepatitis B screening in at-risk Asian American patients: A randomized, controlled trial, " Digestive Diseases and Sciences, vol. 58, no. 3, pp. 807-814, 2013.
-
(2013)
Digestive Diseases and Sciences
, vol.58
, Issue.3
, pp. 807-814
-
-
Hsu, L.1
Bowlus, C.L.2
Stewart, S.L.3
-
42
-
-
84923486405
-
Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department
-
J. W. Galbraith, R. A. Franco, J. P. Donnelly et al., "Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department, " Hepatology, vol. 61, no. 3, pp. 776-782, 2015.
-
(2015)
Hepatology
, vol.61
, Issue.3
, pp. 776-782
-
-
Galbraith, J.W.1
Franco, R.A.2
Donnelly, J.P.3
-
43
-
-
84938211526
-
Implementing hospital-based baby boomer hepatitis C virus screening and linkage to care: Strategies, results, and costs
-
B. J. Turner, B. S. Taylor, J. T. Hanson et al., "Implementing hospital-based baby boomer hepatitis C virus screening and linkage to care: strategies, results, and costs, " Journal of Hospital Medicine, vol. 10, no. 8, pp. 510-516, 2015.
-
(2015)
Journal of Hospital Medicine
, vol.10
, Issue.8
, pp. 510-516
-
-
Turner, B.J.1
Taylor, B.S.2
Hanson, J.T.3
-
44
-
-
84878930046
-
Birth cohort screening for chronic hepatitis during colonoscopy appointments
-
D. M. Sears, D. C. Cohen, K. Ackerman, J. E. Ma, and J. Song, "Birth cohort screening for chronic hepatitis during colonoscopy appointments, " American Journal of Gastroenterology, vol. 108, no. 6, pp. 981-989, 2013.
-
(2013)
American Journal of Gastroenterology
, vol.108
, Issue.6
, pp. 981-989
-
-
Sears, D.M.1
Cohen, D.C.2
Ackerman, K.3
Ma, J.E.4
Song, J.5
-
45
-
-
84952780055
-
Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: A cross-sectional study
-
R. P. Myers, P. Crotty, S. Town et al., "Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: A cross-sectional study, " CMAJ Open, vol. 3, no. 1, pp. E62-E67, 2015.
-
(2015)
CMAJ Open
, vol.3
, Issue.1
, pp. E62-E67
-
-
Myers, R.P.1
Crotty, P.2
Town, S.3
-
46
-
-
84947553516
-
Epidemiology of hepatitis C virus: A battle on new frontiers
-
N. J. Shire and K. E. Sherman, "Epidemiology of hepatitis C virus: A battle on new frontiers, " Gastroenterology Clinics of North America, vol. 44, no. 4, pp. 699-716, 2015.
-
(2015)
Gastroenterology Clinics of North America
, vol.44
, Issue.4
, pp. 699-716
-
-
Shire, N.J.1
Sherman, K.E.2
-
47
-
-
44849129152
-
Costeffectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups
-
J. Nakamura, K. Terajima, Y. Aoyagi, and K. Akazawa, "Costeffectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups, " The Tohoku Journal of ExperimentalMedicine, vol. 215, no. 1, pp. 33-42, 2008.
-
(2008)
The Tohoku Journal of ExperimentalMedicine
, vol.215
, Issue.1
, pp. 33-42
-
-
Nakamura, J.1
Terajima, K.2
Aoyagi, Y.3
Akazawa, K.4
-
48
-
-
84876190039
-
Infection with hepatitis B and C virus in Europe: A systematic review of prevalence and costeffectiveness of screening
-
S. J. M. Hahné, I. K. Veldhuijzen, L. Wiessing, T.-A. Lim, M. Salminen, and M. V. D. Laar, "Infection with hepatitis B and C virus in Europe: A systematic review of prevalence and costeffectiveness of screening, " BMC Infectious Diseases, vol. 13, no. 1, article 181, 2013.
-
(2013)
BMC Infectious Diseases
, vol.13
, Issue.1
-
-
Hahné, S.J.M.1
Veldhuijzen, I.K.2
Wiessing, L.3
Lim, T.-A.4
Salminen, M.5
Laar, M.V.D.6
-
49
-
-
84929518027
-
Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe
-
A. Kautz, L. Chavdarova, and M. Walker, "Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe, " BMC InfectiousDiseases, vol. 14, supplement 6, article S3, 2014.
-
(2014)
BMC InfectiousDiseases
, vol.14
-
-
Kautz, A.1
Chavdarova, L.2
Walker, M.3
-
50
-
-
84947564170
-
Hepatitis C virus: A European perspective
-
G. Dultz and S. Zeuzem, "Hepatitis C virus: A European perspective, " Gastroenterology Clinics of North America, vol. 44, no. 4, pp. 807-824, 2015.
-
(2015)
Gastroenterology Clinics of North America
, vol.44
, Issue.4
, pp. 807-824
-
-
Dultz, G.1
Zeuzem, S.2
-
51
-
-
84880174906
-
Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response
-
S. Lubega, U. Agbim, M. Surjadi, M. Mahoney, and M. Khalili, "Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response, " Liver International, vol. 33, no. 7, pp. 999-1007, 2013.
-
(2013)
Liver International
, vol.33
, Issue.7
, pp. 999-1007
-
-
Lubega, S.1
Agbim, U.2
Surjadi, M.3
Mahoney, M.4
Khalili, M.5
-
52
-
-
84865091292
-
Provider and patient correlates of provider decisions to recommend HCV treatment to HIV Co-infected patients
-
G. Wagner, K. C. Osilla, J. Garnett et al., "Provider and patient correlates of provider decisions to recommend HCV treatment to HIV Co-infected patients, " Journal of the International Association of Physicians in AIDS Care, vol. 11, no. 4, pp. 245-251, 2012.
-
(2012)
Journal of the International Association of Physicians in AIDS Care
, vol.11
, Issue.4
, pp. 245-251
-
-
Wagner, G.1
Osilla, K.C.2
Garnett, J.3
-
53
-
-
84898984691
-
Hepatitis and liver disease knowledge and preventive practices among health workers in Mexico: A cross-sectional study
-
N. Islam, Y. N. Flores, P. Ramirez, R. Bastani, and J. Salmerón, "Hepatitis and liver disease knowledge and preventive practices among health workers in Mexico: A cross-sectional study, " International Journal of PublicHealth, vol. 59, no. 2, pp. 381-394, 2014.
-
(2014)
International Journal of PublicHealth
, vol.59
, Issue.2
, pp. 381-394
-
-
Islam, N.1
Flores, Y.N.2
Ramirez, P.3
Bastani, R.4
Salmerón, J.5
-
54
-
-
79952675044
-
Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia
-
J. Grebely, J. Bryant, P. Hull et al., "Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia, " Journal of Viral Hepatitis, vol. 18, no. 4, pp. e104-e116, 2011.
-
(2011)
Journal of Viral Hepatitis
, vol.18
, Issue.4
, pp. e104-e116
-
-
Grebely, J.1
Bryant, J.2
Hull, P.3
-
55
-
-
84891352634
-
Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America
-
J. A. Aberg, J. E. Gallant, K. G. Ghanem, P. Emmanuel, B. S. Zingman, and M. A. Horberg, "Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America, " Clinical Infectious Diseases, vol. 58, no. 1, pp. 1-10, 2014.
-
(2014)
Clinical Infectious Diseases
, vol.58
, Issue.1
, pp. 1-10
-
-
Aberg, J.A.1
Gallant, J.E.2
Ghanem, K.G.3
Emmanuel, P.4
Zingman, B.S.5
Horberg, M.A.6
-
56
-
-
84864150288
-
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men
-
B. P. Linas, A. Y. Wong, B. R. Schackman, A. Y. Kim, and K. A. Freedberg, "Cost-effective screening for acute hepatitis C virus infection in hiv-infected men who have sex with men, " Clinical Infectious Diseases, vol. 55, no. 2, pp. 279-290, 2012.
-
(2012)
Clinical Infectious Diseases
, vol.55
, Issue.2
, pp. 279-290
-
-
Linas, B.P.1
Wong, A.Y.2
Schackman, B.R.3
Kim, A.Y.4
Freedberg, K.A.5
-
57
-
-
84868032525
-
Hepatitis C virus infections in the swiss HIV cohort study: A rapidly evolving epidemic
-
G. Wandeler, T. Gsponer, A. Bregenzer et al., "Hepatitis C virus infections in the swiss HIV cohort study: A rapidly evolving epidemic, " Clinical Infectious Diseases, vol. 55, no. 10, pp. 1408-1416, 2012.
-
(2012)
Clinical Infectious Diseases
, vol.55
, Issue.10
, pp. 1408-1416
-
-
Wandeler, G.1
Gsponer, T.2
Bregenzer, A.3
-
58
-
-
84878879884
-
Incident hepatitis C virus infection in men who have sex with men: A prospective cohort analysis, 1984-2011
-
M. D. Witt, E. C. Seaberg, A. Darilay et al., "Incident hepatitis C virus infection in men who have sex with men: A prospective cohort analysis, 1984-2011, " Clinical Infectious Diseases, vol. 57, no. 1, pp. 77-84, 2013.
-
(2013)
Clinical Infectious Diseases
, vol.57
, Issue.1
, pp. 77-84
-
-
Witt, M.D.1
Seaberg, E.C.2
Darilay, A.3
-
59
-
-
84866175677
-
HCV seroconversion among never-injecting heroin users at baseline: No predictorsidentified other than starting injection
-
M. J. Bravo, F. Vallejo, G. Barrio et al., "HCV seroconversion among never-injecting heroin users at baseline: no predictorsidentified other than starting injection, " International Journal of Drug Policy, vol. 23, no. 5, pp. 415-419, 2012.
-
(2012)
International Journal of Drug Policy
, vol.23
, Issue.5
, pp. 415-419
-
-
Bravo, M.J.1
Vallejo, F.2
Barrio, G.3
-
60
-
-
79951522447
-
Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
-
I. T. Williams, B. P. Bell, W. Kuhnert, andM. J. Alter, "Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006, " Archives of Internal Medicine, vol. 171, no. 3, pp. 242-248, 2011.
-
(2011)
Archives of Internal Medicine
, vol.171
, Issue.3
, pp. 242-248
-
-
Williams, I.T.1
Bell, B.P.2
Kuhnert, W.3
Alter, M.J.4
-
61
-
-
84941807523
-
Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum
-
J. P. Meyer, Y. Moghimi, R. Marcus, J. K. Lim, A. H. Litwin, and F. L. Altice, "Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum, " International Journal of Drug Policy, vol. 26, no. 10, pp. 922-935, 2015.
-
(2015)
International Journal of Drug Policy
, vol.26
, Issue.10
, pp. 922-935
-
-
Meyer, J.P.1
Moghimi, Y.2
Marcus, R.3
Lim, J.K.4
Litwin, A.H.5
Altice, F.L.6
-
62
-
-
84871245811
-
Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study
-
A. C. Moorman, S. C. Gordon, L. B. Rupp et al., "Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study, " Clinical Infectious Diseases, vol. 56, no. 1, pp. 40-50, 2013.
-
(2013)
Clinical Infectious Diseases
, vol.56
, Issue.1
, pp. 40-50
-
-
Moorman, A.C.1
Gordon, S.C.2
Rupp, L.B.3
-
63
-
-
84987623638
-
Evaluating a hepatitis c quality gap: Missed opportunities for HCV-related cares
-
Y. Liu, R. H. Lawrence, Y. Falck-Ytter, B. Watts, andA. A. Hirsch, "Evaluating a hepatitis c quality gap: missed opportunities for HCV-related cares, " American Journal ofManaged Care, vol. 20, no. 7, pp. e257-e264, 2014.
-
(2014)
American Journal OfManaged Care
, vol.20
, Issue.7
, pp. e257-e264
-
-
Liu, Y.1
Lawrence, R.H.2
Falck-Ytter, Y.3
Watts, B.4
Hirsch, A.A.5
-
64
-
-
34247200049
-
Reasons why patients infected with chronic hepatitisCvirus choose to defer treatment: Do they alter their decision with time?
-
O. S. Khokhar and J. H. Lewis, "Reasons why patients infected with chronic hepatitisCvirus choose to defer treatment: do they alter their decision with time?" Digestive Diseases and Sciences, vol. 52, no. 5, pp. 1168-1176, 2007.
-
(2007)
Digestive Diseases and Sciences
, vol.52
, Issue.5
, pp. 1168-1176
-
-
Khokhar, O.S.1
Lewis, J.H.2
-
65
-
-
79958195203
-
Outcomes of treatment for hepatitis C virus infection by primary care providers
-
S. Arora, K. Thornton, G. Murata et al., "Outcomes of treatment for hepatitis C virus infection by primary care providers, " New England Journal of Medicine, vol. 364, no. 23, pp. 2199-2207, 2011.
-
(2011)
New England Journal of Medicine
, vol.364
, Issue.23
, pp. 2199-2207
-
-
Arora, S.1
Thornton, K.2
Murata, G.3
-
66
-
-
84867714206
-
Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection
-
B. T. Clark, G. Garcia-Tsao, and L. Fraenkel, "Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection, " Patient Preference and Adherence, vol. 6, pp. 285-295, 2012.
-
(2012)
Patient Preference and Adherence
, vol.6
, pp. 285-295
-
-
Clark, B.T.1
Garcia-Tsao, G.2
Fraenkel, L.3
-
67
-
-
84949561087
-
Update on hepatitis C: Direct-acting antivirals
-
L. L. Seifert, R. B. Perumpail, and A. Ahmed, "Update on hepatitis C: direct-acting antivirals, " World Journal of Hepatology, vol. 7, no. 28, pp. 2829-2833, 2015.
-
(2015)
World Journal of Hepatology
, vol.7
, Issue.28
, pp. 2829-2833
-
-
Seifert, L.L.1
Perumpail, R.B.2
Ahmed, A.3
-
69
-
-
84877755305
-
Hepatitis C in the United States
-
S. D. Holmberg, P. R. Spradling, A. C. Moorman, and M. M. Denniston, "Hepatitis C in the United States, " The New England Journal of Medicine, vol. 368, no. 20, pp. 1859-1861, 2013.
-
(2013)
The New England Journal of Medicine
, vol.368
, Issue.20
, pp. 1859-1861
-
-
Holmberg, S.D.1
Spradling, P.R.2
Moorman, A.C.3
Denniston, M.M.4
-
70
-
-
67651083226
-
Hepatitis C treatment for injection drug users: A review of the available evidence
-
M. Hellard, R. Sacks?Davis, and J. Gold, "Hepatitis C treatment for injection drug users: A review of the available evidence, " Clinical Infectious Diseases, vol. 49, no. 4, pp. 561-573, 2009.
-
(2009)
Clinical Infectious Diseases
, vol.49
, Issue.4
, pp. 561-573
-
-
Hellard, M.1
Sacksdavis, R.2
Gold, J.3
-
71
-
-
23744484452
-
Barriers to the treatment of hepatitis C: Patient, provider, and system factors
-
J. A. Morrill, M. Shrestha, and R. W. Grant, "Barriers to the treatment of hepatitis C: patient, provider, and system factors, " Journal of General InternalMedicine, vol. 20, no. 8, pp. 754-758, 2005.
-
(2005)
Journal of General InternalMedicine
, vol.20
, Issue.8
, pp. 754-758
-
-
Morrill, J.A.1
Shrestha, M.2
Grant, R.W.3
-
72
-
-
84901658602
-
Lack of access to treatment as a barrier to HCV screening: A facility-based assessment in the Indian health service
-
B. Reilley, J. Leston, J. T. Redd, and R. Geiger, "Lack of access to treatment as a barrier to HCV screening: A facility-based assessment in the Indian health service, " Journal of PublicHealth Management and Practice, vol. 20, no. 4, pp. 420-423, 2014.
-
(2014)
Journal of PublicHealth Management and Practice
, vol.20
, Issue.4
, pp. 420-423
-
-
Reilley, B.1
Leston, J.2
Redd, J.T.3
Geiger, R.4
-
73
-
-
84876153751
-
A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care
-
C. E. McGowan, A. Monis, B. R. Bacon et al., "A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care, " Hepatology, vol. 57, no. 4, pp. 1325-1332, 2013.
-
(2013)
Hepatology
, vol.57
, Issue.4
, pp. 1325-1332
-
-
McGowan, C.E.1
Monis, A.2
Bacon, B.R.3
-
74
-
-
84868151001
-
Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre
-
M. M. Islam, L. Topp, K. M. Conigrave et al., "Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre, " Journal of Substance Abuse Treatment, vol. 43, no. 4, pp. 440-445, 2012.
-
(2012)
Journal of Substance Abuse Treatment
, vol.43
, Issue.4
, pp. 440-445
-
-
Islam, M.M.1
Topp, L.2
Conigrave, K.M.3
-
75
-
-
84868147307
-
Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program
-
M. R. Stein, I. J. Soloway, K. S. Jefferson, R. J. Roose, J. H. Arnsten, and A. H. Litwin, "Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program, " Journal of Substance Abuse Treatment, vol. 43, no. 4, pp. 424-432, 2012.
-
(2012)
Journal of Substance Abuse Treatment
, vol.43
, Issue.4
, pp. 424-432
-
-
Stein, M.R.1
Soloway, I.J.2
Jefferson, K.S.3
Roose, R.J.4
Arnsten, J.H.5
Litwin, A.H.6
-
76
-
-
84881004592
-
Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all
-
P. Bruggmann and A. H. Litwin, "Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all, " Clinical Infectious Diseases, vol. 57, supplement 2, pp. S56-S61, 2013.
-
(2013)
Clinical Infectious Diseases
, vol.57
, pp. S56-S61
-
-
Bruggmann, P.1
Litwin, A.H.2
-
77
-
-
84944279905
-
Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse
-
S. B. Ho, N. Bräu, R. Cheung et al., "Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse, " Clinical Gastroenterology and Hepatology, vol. 13, no. 11, pp. 2005-2014, 2015.
-
(2015)
Clinical Gastroenterology and Hepatology
, vol.13
, Issue.11
, pp. 2005-2014
-
-
Ho, S.B.1
Bräu, N.2
Cheung, R.3
-
78
-
-
84890122831
-
Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation inNorthern California
-
L. Rossaro, C. Torruellas, S. Dhaliwal et al., "Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation inNorthern California, " Digestive Diseases and Sciences, vol. 58, no. 12, pp. 3620-3625, 2013.
-
(2013)
Digestive Diseases and Sciences
, vol.58
, Issue.12
, pp. 3620-3625
-
-
Rossaro, L.1
Torruellas, C.2
Dhaliwal, S.3
-
79
-
-
84865422792
-
Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic
-
L. Miller, S.-A. Fluker, M. Osborn, X. Liu, and A. Strawder, "Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic, " Journal of the National Medical Association, vol. 104, no. 5-6, pp. 244-250, 2012.
-
(2012)
Journal of the National Medical Association
, vol.104
, Issue.5-6
, pp. 244-250
-
-
Miller, L.1
Fluker, S.-A.2
Osborn, M.3
Liu, X.4
Strawder, A.5
-
80
-
-
84931560419
-
Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program
-
S. B. Trooskin, J. Poceta, C. M. Towey et al., "Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program, " Journal of General Internal Medicine, vol. 30, no. 7, pp. 950-957, 2015.
-
(2015)
Journal of General Internal Medicine
, vol.30
, Issue.7
, pp. 950-957
-
-
Trooskin, S.B.1
Poceta, J.2
Towey, C.M.3
-
81
-
-
84931082688
-
Identification and linkage to care of HCV-infected persons in five health centers-Philadelphia, Pennsylvania, 2012-2014
-
C. Coyle, K. Viner, E. Hughes et al., "Identification and linkage to care of HCV-infected persons in five health centers-Philadelphia, Pennsylvania, 2012-2014, " Morbidity and MortalityWeekly Report, vol. 64, no. 17, pp. 459-463, 2015.
-
(2015)
Morbidity and MortalityWeekly Report
, vol.64
, Issue.17
, pp. 459-463
-
-
Coyle, C.1
Viner, K.2
Hughes, E.3
-
82
-
-
84956871250
-
Advances in hepatitis C therapy: What is the current state-what come's next?
-
S. Zopf, A. E. Kremer, M. F. Neurath, and J. Siebler, "Advances in hepatitis C therapy: what is the current state-what come's next?" World Journal of Hepatology, vol. 8, no. 3, pp. 139-147, 2016.
-
(2016)
World Journal of Hepatology
, vol.8
, Issue.3
, pp. 139-147
-
-
Zopf, S.1
Kremer, A.E.2
Neurath, M.F.3
Siebler, J.4
-
83
-
-
84990028964
-
Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens
-
J. M. Pawlotsky, "Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens, " Gastroenterology, vol. 151, no. 1, pp. 70-86, 2016.
-
(2016)
Gastroenterology
, vol.151
, Issue.1
, pp. 70-86
-
-
Pawlotsky, J.M.1
-
84
-
-
84982792328
-
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance
-
M. Jiménez-Pérez, R. González-Grande, P. España Contreras, I. Pinazo Martnez, J. de la Cruz Lombardo, and R. Olmedo Martn, "Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance, "World Journal of Gastroenterology, vol. 22, no. 29, pp. 6573-6581, 2016.
-
(2016)
World Journal of Gastroenterology
, vol.22
, Issue.29
, pp. 6573-6581
-
-
Jiménez-Pérez, M.1
González-Grande, R.2
España Contreras, P.3
Pinazo Martnez, I.4
Lombardo Cruz De La, J.5
Olmedo Martn, R.6
-
85
-
-
84975244053
-
Hepatitis C genotype 3 disease
-
S. Kattakuzhy, R. Levy, E. Rosenthal, L. Tang, E. Wilson, and S. Kottilil, "Hepatitis C genotype 3 disease, " Hepatology International, 2016.
-
(2016)
Hepatology International
-
-
Kattakuzhy, S.1
Levy, R.2
Rosenthal, E.3
Tang, L.4
Wilson, E.5
Kottilil, S.6
-
86
-
-
84943328674
-
Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients
-
J. Dietz, S. Susser, C. Berkowski, D. Perner, S. Zeuzem, and C. Sarrazin, "Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients, " PLoS ONE, vol. 10, no. 8, article e0134395, 2015.
-
(2015)
PLoS ONE
, vol.10
, Issue.8
-
-
Dietz, J.1
Susser, S.2
Berkowski, C.3
Perner, D.4
Zeuzem, S.5
Sarrazin, C.6
-
87
-
-
84873041135
-
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment
-
D. J. Bartels, J. C. Sullivan, E. Z. Zhang et al., "Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment, " Journal ofVirology, vol. 87, no. 3, pp. 1544-1553, 2013.
-
(2013)
Journal OfVirology
, vol.87
, Issue.3
, pp. 1544-1553
-
-
Bartels, D.J.1
Sullivan, J.C.2
Zhang, E.Z.3
-
88
-
-
84896520682
-
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
-
M. D. Schneider and C. Sarrazin, "Antiviral therapy of hepatitis C in 2014: do we need resistance testing?" Antiviral Research, vol. 105, no. 1, pp. 64-71, 2014.
-
(2014)
Antiviral Research
, vol.105
, Issue.1
, pp. 64-71
-
-
Schneider, M.D.1
Sarrazin, C.2
-
89
-
-
84927798764
-
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
-
O. Lenz, T. Verbinnen, B. Fevery et al., "Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies, " Journal of Hepatology, vol. 62, no. 5, pp. 1008-1014, 2015.
-
(2015)
Journal of Hepatology
, vol.62
, Issue.5
, pp. 1008-1014
-
-
Lenz, O.1
Verbinnen, T.2
Fevery, B.3
-
90
-
-
84936804505
-
Successes and challenges on the road to cure hepatitisC
-
S. M. Horner, S. Naggie, and R. C. Condit, "Successes and challenges on the road to cure hepatitisC, " PLoS Pathogens, vol. 11, no. 6, article e1004854, 2015.
-
(2015)
PLoS Pathogens
, vol.11
, Issue.6
-
-
Horner, S.M.1
Naggie, S.2
Condit, R.C.3
-
91
-
-
84958161018
-
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients
-
I. Vicenti, F. Falasca, L. Sticchi, B. Bruzzone, O. Turriziani, and M. Zazzi, "Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients, " Journal of Clinical Virology, vol. 76, pp. 20-23, 2016.
-
(2016)
Journal of Clinical Virology
, vol.76
, pp. 20-23
-
-
Vicenti, I.1
Falasca, F.2
Sticchi, L.3
Bruzzone, B.4
Turriziani, O.5
Zazzi, M.6
-
92
-
-
84906053496
-
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebocontrolled trial
-
I. M. Jacobson, G. J. Dore, G. R. Foster et al., "Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebocontrolled trial, " The Lancet, vol. 384, no. 9941, pp. 403-413, 2014.
-
(2014)
The Lancet
, vol.384
, Issue.9941
, pp. 403-413
-
-
Jacobson, I.M.1
Dore, G.J.2
Foster, G.R.3
-
93
-
-
84906059095
-
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatmentnaive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebocontrolled phase 3 trial
-
M. Manns, P. Marcellin, F. Poordad et al., "Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatmentnaive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebocontrolled phase 3 trial, " The Lancet, vol. 384, no. 9941, pp. 414-426, 2014.
-
(2014)
The Lancet
, vol.384
, Issue.9941
, pp. 414-426
-
-
Manns, M.1
Marcellin, P.2
Poordad, F.3
-
94
-
-
84901217985
-
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial
-
X. Forns, E. Lawitz, S. Zeuzem et al., "Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial, " Gastroenterology, vol. 146, no. 7, pp. 1669. e3-1679. e3, 2014.
-
(2014)
Gastroenterology
, vol.146
, Issue.7
, pp. 1669e3-1679e3
-
-
Forns, X.1
Lawitz, E.2
Zeuzem, S.3
-
95
-
-
84925619517
-
Efficacy and safety of simeprevir with PegIFN/ribavirin in nä?ve or experienced patients infected with chronic HCV genotype 4
-
C. Moreno, C. Hezode, P. Marcellin et al., "Efficacy and safety of simeprevir with PegIFN/ribavirin in nä?ve or experienced patients infected with chronic HCV genotype 4, " Journal of Hepatology, vol. 62, no. 5, pp. 1047-1055, 2015.
-
(2015)
Journal of Hepatology
, vol.62
, Issue.5
, pp. 1047-1055
-
-
Moreno, C.1
Hezode, C.2
Marcellin, P.3
-
96
-
-
84922318694
-
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
-
C. Sarrazin, E. Lathouwers, M. Peeters et al., "Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region, " Antiviral Research, vol. 116, pp. 10-16, 2015.
-
(2015)
Antiviral Research
, vol.116
, pp. 10-16
-
-
Sarrazin, C.1
Lathouwers, E.2
Peeters, M.3
-
97
-
-
84936936737
-
Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: Implication for simeprevir usage
-
L. L. Vidãl, A. F. Santos, and M. A. Soares, "Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage, " Journal of Antimicrobial Chemotherapy, vol. 70, no. 7, Article ID dkv081, pp. 2024-2027, 2014.
-
(2014)
Journal of Antimicrobial Chemotherapy
, vol.70
, Issue.7
, pp. 2024-2027
-
-
Vidãl, L.L.1
Santos, A.F.2
Soares, M.A.3
-
98
-
-
84940498353
-
Diversity of 1, 213 hepatitis C virus NS3 protease sequences froma clinical virology laboratory database inMarseille university hospitals, southeastern France
-
H. Hajji, S. Aherfi, A. Motte et al., "Diversity of 1, 213 hepatitis C virus NS3 protease sequences froma clinical virology laboratory database inMarseille university hospitals, southeastern France, " Journal of Medical Virology, vol. 87, no. 11, pp. 1921-1933, 2015.
-
(2015)
Journal of Medical Virology
, vol.87
, Issue.11
, pp. 1921-1933
-
-
Hajji, H.1
Aherfi, S.2
Motte, A.3
-
99
-
-
84979066379
-
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)
-
E. Lawitz, G. Matusow, E. DeJesus et al., "Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2), " Hepatology, vol. 64, no. 2, pp. 360-369, 2016.
-
(2016)
Hepatology
, vol.64
, Issue.2
, pp. 360-369
-
-
Lawitz, E.1
Matusow, G.2
DeJesus, E.3
-
100
-
-
84954399628
-
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
-
C. Sarrazin, "The importance of resistance to direct antiviral drugs in HCV infection in clinical practice, " Journal of Hepatology, vol. 64, no. 2, pp. 486-504, 2016.
-
(2016)
Journal of Hepatology
, vol.64
, Issue.2
, pp. 486-504
-
-
Sarrazin, C.1
-
101
-
-
77956116880
-
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system
-
R. A. Fridell, D. Qiu, C. Wang, L. Valera, andM. Gao, "Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system, " Antimicrobial Agents and Chemotherapy, vol. 54, no. 9, pp. 3641-3650, 2010.
-
(2010)
Antimicrobial Agents and Chemotherapy
, vol.54
, Issue.9
, pp. 3641-3650
-
-
Fridell, R.A.1
Qiu, D.2
Wang, C.3
Valera, L.4
Gao, M.5
-
102
-
-
84879693219
-
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
-
Y. Suzuki, K. Ikeda, F. Suzuki et al., "Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options, " Journal of Hepatology, vol. 58, no. 4, pp. 655-662, 2013.
-
(2013)
Journal of Hepatology
, vol.58
, Issue.4
, pp. 655-662
-
-
Suzuki, Y.1
Ikeda, K.2
Suzuki, F.3
-
103
-
-
84863860109
-
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
-
F. Suzuki, H. Sezaki, N. Akuta et al., "Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b, " Journal of Clinical Virology, vol. 54, no. 4, pp. 352-354, 2012.
-
(2012)
Journal of Clinical Virology
, vol.54
, Issue.4
, pp. 352-354
-
-
Suzuki, F.1
Sezaki, H.2
Akuta, N.3
-
104
-
-
84979911433
-
Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals
-
N. Coppola, C. Minichini, M. Starace, C. Sagnelli, and E. Sagnelli, "Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals, " Journal ofMedical Virology, vol. 88, no. 10, pp. 1659-1671, 2016.
-
(2016)
Journal OfMedical Virology
, vol.88
, Issue.10
, pp. 1659-1671
-
-
Coppola, N.1
Minichini, C.2
Starace, M.3
Sagnelli, C.4
Sagnelli, E.5
-
105
-
-
84964762303
-
Long-term followup of treatment-emergent resistance-associated variants in NS3, NS5A and NS5 B with paritaprevir/r-, ombitasvir-and dasabuvir-based regimens
-
P. Krishnan, R. Tripathi, G. Schnell et al., "Long-term followup of treatment-emergent resistance-associated variants in NS3, NS5A and NS5 B with paritaprevir/r-, ombitasvir-and dasabuvir-based regimens, " Journal of Hepatology, vol. 62, supplement 2, p. S220, 2015.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S220
-
-
Krishnan, P.1
Tripathi, R.2
Schnell, G.3
-
106
-
-
84883219967
-
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
-
F. Mcphee, D. Hernandez, F. Yu et al., "Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir, " Hepatology, vol. 58, no. 3, pp. 902-911, 2013.
-
(2013)
Hepatology
, vol.58
, Issue.3
, pp. 902-911
-
-
Mcphee, F.1
Hernandez, D.2
Yu, F.3
-
107
-
-
84964762607
-
Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir
-
H. Dvory-Sobol, D. Wyles, W. Ouyang et al., "Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir, " Journal of Hepatology, vol. 62, supplement 2, p. S221, 2015.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S221
-
-
Dvory-Sobol, H.1
Wyles, D.2
Ouyang, W.3
-
108
-
-
84942864509
-
Resistance to directacting antiviral agents: Clinical utility and significance
-
V. Cento, S. Chevaliez, and C. F. Perno, "Resistance to directacting antiviral agents: clinical utility and significance, " Current Opinion in HIV and AIDS, vol. 10, no. 5, pp. 381-389, 2015.
-
(2015)
Current Opinion in HIV and AIDS
, vol.10
, Issue.5
, pp. 381-389
-
-
Cento, V.1
Chevaliez, S.2
Perno, C.F.3
-
109
-
-
84946945495
-
Management of direct-acting antiviral agent failures
-
M. Buti, M. Riveiro-Barciela, and R. Esteban, "Management of direct-acting antiviral agent failures, " Journal of Hepatology, vol. 63, no. 6, pp. 1511-1522, 2015.
-
(2015)
Journal of Hepatology
, vol.63
, Issue.6
, pp. 1511-1522
-
-
Buti, M.1
Riveiro-Barciela, M.2
Esteban, R.3
-
110
-
-
40849097775
-
Rates of evolutionary change in viruses: Patterns and determinants
-
S. Duffy, L. A. Shackelton, and E. C. Holmes, "Rates of evolutionary change in viruses: patterns and determinants, " Nature Reviews Genetics, vol. 9, no. 4, pp. 267-276, 2008.
-
(2008)
Nature Reviews Genetics
, vol.9
, Issue.4
, pp. 267-276
-
-
Duffy, S.1
Shackelton, L.A.2
Holmes, E.C.3
-
111
-
-
0028945033
-
Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
-
J. Bukh, R. H. Miller, and R. H. Purcell, "Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes, " Seminars in Liver Disease, vol. 15, no. 1, pp. 41-63, 1995.
-
(1995)
Seminars in Liver Disease
, vol.15
, Issue.1
, pp. 41-63
-
-
Bukh, J.1
Miller, R.H.2
Purcell, R.H.3
-
112
-
-
0033429088
-
Viral heterogeneity of the hepatitis C virus
-
P. Simmonds, "Viral heterogeneity of the hepatitis C virus, " Journal of Hepatology, vol. 31, supplement 1, pp. 54-60, 1999.
-
(1999)
Journal of Hepatology
, vol.31
, pp. 54-60
-
-
Simmonds, P.1
-
113
-
-
22344448015
-
Mutational escape fromCD8+ T cell immunity: HCV evolution, from chimpanzees to man
-
D. G. Bowen and C. M. Walker, "Mutational escape fromCD8+ T cell immunity: HCV evolution, from chimpanzees to man, " Journal of ExperimentalMedicine, vol. 201, no. 11, pp. 1709-1714, 2005.
-
(2005)
Journal of ExperimentalMedicine
, vol.201
, Issue.11
, pp. 1709-1714
-
-
Bowen, D.G.1
Walker, C.M.2
-
114
-
-
33847015308
-
HepatitisCvirus continuously escapes fromneutralizing antibody and T-cell responses during chronic infection in vivo
-
T. vonHahn, J. C. Yoon, H. Alter et al., "HepatitisCvirus continuously escapes fromneutralizing antibody and T-cell responses during chronic infection in vivo, " Gastroenterology, vol. 132, no. 2, pp. 667-678, 2007.
-
(2007)
Gastroenterology
, vol.132
, Issue.2
, pp. 667-678
-
-
VonHahn, T.1
Yoon, J.C.2
Alter, H.3
-
115
-
-
34249885360
-
Chronic infections with hepatotropic viruses: Mechanisms of impairment of cellular immune responses
-
B. Rehermann, "Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses, " Seminars in Liver Disease, vol. 27, no. 2, pp. 152-160, 2007.
-
(2007)
Seminars in Liver Disease
, vol.27
, Issue.2
, pp. 152-160
-
-
Rehermann, B.1
-
116
-
-
33947421722
-
Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection
-
A. Penna, M. Pilli, A. Zerbini et al., "Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection, " Hepatology, vol. 45, no. 3, pp. 588-601, 2007.
-
(2007)
Hepatology
, vol.45
, Issue.3
, pp. 588-601
-
-
Penna, A.1
Pilli, M.2
Zerbini, A.3
-
117
-
-
85027929950
-
Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation
-
J. R. Larrubia, M. U. Lokhande, S. Garca-Garzõn et al., "Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation, " Journal of Viral Hepatitis, vol. 20, no. 2, pp. 85-94, 2013.
-
(2013)
Journal of Viral Hepatitis
, vol.20
, Issue.2
, pp. 85-94
-
-
Larrubia, J.R.1
Lokhande, M.U.2
Garca-Garzõn, S.3
-
118
-
-
38649100951
-
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies
-
J. M. Timpe, Z. Stamataki, A. Jennings et al., "Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies, " Hepatology, vol. 47, no. 1, pp. 17-24, 2008.
-
(2008)
Hepatology
, vol.47
, Issue.1
, pp. 17-24
-
-
Timpe, J.M.1
Stamataki, Z.2
Jennings, A.3
-
119
-
-
84947425793
-
Progress in the development of vaccines for hepatitis C virus infection
-
F. Ghasemi, S. Rostami, and Z. Meshkat, "Progress in the development of vaccines for hepatitis C virus infection, " World Journal of Gastroenterology, vol. 21, no. 42, pp. 11984-12002, 2015.
-
(2015)
World Journal of Gastroenterology
, vol.21
, Issue.42
, pp. 11984-12002
-
-
Ghasemi, F.1
Rostami, S.2
Meshkat, Z.3
-
120
-
-
84885335829
-
Hepatitis C virus infection and related liver disease: The quest for the best animal model
-
L. Mailly, E. Robinet, P. Meuleman, T. F. Baumert, and M. B. Zeisel, "Hepatitis C virus infection and related liver disease: The quest for the best animal model, " Frontiers in Microbiology, vol. 4, article 213, 2013.
-
(2013)
Frontiers in Microbiology
, vol.4
-
-
Mailly, L.1
Robinet, E.2
Meuleman, P.3
Baumert, T.F.4
Zeisel, M.B.5
-
121
-
-
84860287115
-
Animal models for the study of hepatitis C virus infection and related liver disease
-
J. Bukh, "Animal models for the study of hepatitis C virus infection and related liver disease, " Gastroenterology, vol. 142, no. 6, pp. 1279. e3-1287. e3, 2012.
-
(2012)
Gastroenterology
, vol.142
, Issue.6
, pp. 1279e3-1287e3
-
-
Bukh, J.1
-
122
-
-
84905870295
-
Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy
-
F. Ansaldi, A. Orsi, L. Sticchi, B. Bruzzone, and G. Icardi, "Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy, " World Journal of Gastroenterology, vol. 20, no. 29, pp. 9633-9652, 2014.
-
(2014)
World Journal of Gastroenterology
, vol.20
, Issue.29
, pp. 9633-9652
-
-
Ansaldi, F.1
Orsi, A.2
Sticchi, L.3
Bruzzone, B.4
Icardi, G.5
-
123
-
-
3843137346
-
A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers
-
G. Leroux-Roels, E. Depla, F. Hulstaert et al., "A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers, " Vaccine, vol. 22, no. 23-24, pp. 3080-3086, 2004.
-
(2004)
Vaccine
, vol.22
, Issue.23-24
, pp. 3080-3086
-
-
Leroux-Roels, G.1
Depla, E.2
Hulstaert, F.3
-
124
-
-
77955661037
-
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
-
S. E. Frey, M. Houghton, S. Coates et al., "Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults, " Vaccine, vol. 28, no. 38, pp. 6367-6373, 2010.
-
(2010)
Vaccine
, vol.28
, Issue.38
, pp. 6367-6373
-
-
Frey, S.E.1
Houghton, M.2
Coates, S.3
-
125
-
-
67549123833
-
Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX- vaccine: A phase i study in healthy volunteers
-
D. Drane, E. Maraskovsky, R. Gibson et al., "Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX- vaccine: A phase I study in healthy volunteers, " Human Vaccines, vol. 5, no. 3, pp. 151-157, 2009.
-
(2009)
Human Vaccines
, vol.5
, Issue.3
, pp. 151-157
-
-
Drane, D.1
Maraskovsky, E.2
Gibson, R.3
-
126
-
-
33646144429
-
Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects
-
C. Firbas, B. Jilma, E. Tauber et al., "Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects, " Vaccine, vol. 24, no. 20, pp. 4343-4353, 2006.
-
(2006)
Vaccine
, vol.24
, Issue.20
, pp. 4343-4353
-
-
Firbas, C.1
Jilma, B.2
Tauber, E.3
-
127
-
-
77549085401
-
Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine
-
C. Firbas, T. Boehm, V. Buerger et al., "Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine, " Vaccine, vol. 28, no. 12, pp. 2397-2407, 2010.
-
(2010)
Vaccine
, vol.28
, Issue.12
, pp. 2397-2407
-
-
Firbas, C.1
Boehm, T.2
Buerger, V.3
-
128
-
-
84855388574
-
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
-
E. Barnes, A. Folgori, S. Capone et al., "Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man, " Science Translational Medicine, vol. 4, no. 115, Article ID 115ra1, 2012.
-
(2012)
Science Translational Medicine
, vol.4
, Issue.115
-
-
Barnes, E.1
Folgori, A.2
Capone, S.3
-
129
-
-
84954436919
-
Status of hepatitis C virus vaccination: Recent update
-
K. S. Abdelwahab and Z. N. A. Said, "Status of hepatitis C virus vaccination: recent update, " World Journal of Gastroenterology, vol. 22, no. 2, pp. 862-873, 2016.
-
(2016)
World Journal of Gastroenterology
, vol.22
, Issue.2
, pp. 862-873
-
-
Abdelwahab, K.S.1
Said, Z.N.A.2
-
130
-
-
42949111104
-
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41
-
C. S. Klade, H. Wedemeyer, T. Berg et al., "Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41, " Gastroenterology, vol. 134, no. 5, pp. 1385. e1-1395. e1, 2008.
-
(2008)
Gastroenterology
, vol.134
, Issue.5
, pp. 1385e1-1395e1
-
-
Klade, C.S.1
Wedemeyer, H.2
Berg, T.3
-
131
-
-
67650734950
-
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C
-
H. Wedemeyer, E. Schuller, V. Schlaphoff et al., "Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C, " Vaccine, vol. 27, no. 37, pp. 5142-5151, 2009.
-
(2009)
Vaccine
, vol.27
, Issue.37
, pp. 5142-5151
-
-
Wedemeyer, H.1
Schuller, E.2
Schlaphoff, V.3
-
132
-
-
34748815771
-
Phase i clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferonbased therapy
-
S. Yutani, A. Yamada, K. Yoshida et al., "Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferonbased therapy, " Vaccine, vol. 25, no. 42, pp. 7429-7435, 2007.
-
(2007)
Vaccine
, vol.25
, Issue.42
, pp. 7429-7435
-
-
Yutani, S.1
Yamada, A.2
Yoshida, K.3
-
133
-
-
80051490030
-
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
-
F. Habersetzer, G. Honnet, C. Bain et al., "A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C, " Gastroenterology, vol. 141, no. 3, pp. 890. e4-899. e4, 2011.
-
(2011)
Gastroenterology
, vol.141
, Issue.3
, pp. 890e4-899e4
-
-
Habersetzer, F.1
Honnet, G.2
Bain, C.3
-
134
-
-
84869202423
-
New therapeutic options for HCV infection in the monoclonal antibody era
-
G. A. Sautto, R. A. Diotti, and M. Clementi, "New therapeutic options for HCV infection in the monoclonal antibody era, " New Microbiologica, vol. 35, no. 4, pp. 387-397, 2012.
-
(2012)
New Microbiologica
, vol.35
, Issue.4
, pp. 387-397
-
-
Sautto, G.A.1
Diotti, R.A.2
Clementi, M.3
-
135
-
-
84871804469
-
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
-
M. Flego, A. Ascione, M. Cianfriglia, and S. Vella, "Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases, " BMC Medicine, vol. 11, article 4, 2013.
-
(2013)
BMC Medicine
, vol.11
-
-
Flego, M.1
Ascione, A.2
Cianfriglia, M.3
Vella, S.4
-
136
-
-
34247893277
-
Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: Safety and antiviral activity
-
E. Galun, N. A. Terrault, R. Eren et al., "Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity, " Journal of Hepatology, vol. 46, no. 1, pp. 37-44, 2007.
-
(2007)
Journal of Hepatology
, vol.46
, Issue.1
, pp. 37-44
-
-
Galun, E.1
Terrault, N.A.2
Eren, R.3
-
137
-
-
33748778214
-
Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study
-
T. D. Schiano, M. Charlton, Z. Younossi et al., "Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study, " Liver Transplantation, vol. 12, no. 9, pp. 1381-1389, 2006.
-
(2006)
Liver Transplantation
, vol.12
, Issue.9
, pp. 1381-1389
-
-
Schiano, T.D.1
Charlton, M.2
Younossi, Z.3
-
138
-
-
84875695802
-
Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: A randomized controlled study
-
R. T. Chung, F. D. Gordon, M. P. Curry et al., "Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: A randomized controlled study, " American Journal of Transplantation, vol. 13, no. 4, pp. 1047-1054, 2013.
-
(2013)
American Journal of Transplantation
, vol.13
, Issue.4
, pp. 1047-1054
-
-
Chung, R.T.1
Gordon, F.D.2
Curry, M.P.3
-
139
-
-
84878089612
-
ARandomized, doubleblind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection
-
D. Gardiner, J. Lalezari, E. Lawitz et al., "ARandomized, doubleblind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection, " PLoS ONE, vol. 8, no. 5, Article IDe63818, 2013.
-
(2013)
PLoS ONE
, vol.8
, Issue.5
-
-
Gardiner, D.1
Lalezari, J.2
Lawitz, E.3
-
140
-
-
84879141840
-
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
-
B. Sangro, C. Gomez-Martin, M. De La Mata et al., "A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, " Journal of Hepatology, vol. 59, no. 1, pp. 81-88, 2013.
-
(2013)
Journal of Hepatology
, vol.59
, Issue.1
, pp. 81-88
-
-
Sangro, B.1
Gomez-Martin, C.2
De La Mata, M.3
-
141
-
-
84934765248
-
Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: Results of a phase-2a placebo-controlled trial
-
W. Halota, P. Ferenci, D. Kozielewicz et al., "Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial, " Journal of Viral Hepatitis, vol. 22, no. 8, pp. 651-657, 2015.
-
(2015)
Journal of Viral Hepatitis
, vol.22
, Issue.8
, pp. 651-657
-
-
Halota, W.1
Ferenci, P.2
Kozielewicz, D.3
-
142
-
-
58149388300
-
Naturally occurring dominant resistancemutations to hepatitis C virus protease and polymerase inhibitors in treatment-nä?ve patients
-
T. Kuntzen, J. Timm, A. Berical et al., "Naturally occurring dominant resistancemutations to hepatitis C virus protease and polymerase inhibitors in treatment-nä?ve patients, " Hepatology, vol. 48, no. 6, pp. 1769-1778, 2008.
-
(2008)
Hepatology
, vol.48
, Issue.6
, pp. 1769-1778
-
-
Kuntzen, T.1
Timm, J.2
Berical, A.3
-
143
-
-
84976260940
-
Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3/4Aprotease variants on the efficacy of boceprevir combined with peginterferon/ribavirin
-
J. A. Howe, J. Long, S. Black et al., "Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3/4Aprotease variants on the efficacy of boceprevir combined with peginterferon/ribavirin, " Open Forum Infectious Diseases, vol. 1, no. 2, 2014.
-
(2014)
Open Forum Infectious Diseases
, vol.1
, Issue.2
-
-
Howe, J.A.1
Long, J.2
Black, S.3
-
144
-
-
84941917709
-
Hepatitis C virus drug resistance-associated substitutions: State of the art summary
-
E. Lontok, P. Harrington, A. Howe et al., "Hepatitis C virus drug resistance-associated substitutions: state of the art summary, " Hepatology, vol. 62, no. 5, pp. 1623-1632, 2015.
-
(2015)
Hepatology
, vol.62
, Issue.5
, pp. 1623-1632
-
-
Lontok, E.1
Harrington, P.2
Howe, A.3
-
145
-
-
84946409452
-
HCVNS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A Case Study
-
B. Bartolini, M. Selleri, A. R. Garbuglia et al., "HCVNS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A Case Study, " Journal of Clinical Virology, vol. 72, pp. 60-65, 2015.
-
(2015)
Journal of Clinical Virology
, vol.72
, pp. 60-65
-
-
Bartolini, B.1
Selleri, M.2
Garbuglia, A.R.3
-
146
-
-
84945466065
-
Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK
-
A. Beloukas, S. King, K. Childs et al., "Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK, " Clinical Microbiology and Infection, vol. 21, no. 11, pp. 1033-1039, 2015.
-
(2015)
Clinical Microbiology and Infection
, vol.21
, Issue.11
, pp. 1033-1039
-
-
Beloukas, A.1
King, S.2
Childs, K.3
-
147
-
-
84922981045
-
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy
-
L. Boglione, A. De Nicolò, C. S. Cardellino et al., "Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy, " Clinical Microbiology and Infection, vol. 21, no. 2, pp. 205. e1-205. e3, 2015.
-
(2015)
Clinical Microbiology and Infection
, vol.21
, Issue.2
, pp. 205e1-205e3
-
-
Boglione, L.1
De Nicolò, A.2
Cardellino, C.S.3
-
148
-
-
80055075318
-
NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5
-
S. Vallet, F. Viron, C. Henquell et al., "NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5, " Antiviral Therapy, vol. 16, no. 7, pp. 1093-1102, 2011.
-
(2011)
Antiviral Therapy
, vol.16
, Issue.7
, pp. 1093-1102
-
-
Vallet, S.1
Viron, F.2
Henquell, C.3
-
149
-
-
65449157987
-
Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
-
S. Gaudieri, A. Rauch, K. Pfafferott et al., "Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy, " Hepatology, vol. 49, no. 4, pp. 1069-1082, 2009.
-
(2009)
Hepatology
, vol.49
, Issue.4
, pp. 1069-1082
-
-
Gaudieri, S.1
Rauch, A.2
Pfafferott, K.3
-
150
-
-
84878116773
-
Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors inHepatitis C virus genotypes 1a, 2b and 3a
-
N. Palanisamy, A. Danielsson, C. Kokkula et al., "Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors inHepatitis C virus genotypes 1a, 2b and 3a, " Antiviral Research, vol. 99, no. 1, pp. 12-17, 2013.
-
(2013)
Antiviral Research
, vol.99
, Issue.1
, pp. 12-17
-
-
Palanisamy, N.1
Danielsson, A.2
Kokkula, C.3
-
151
-
-
84937734901
-
Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease
-
N. Nagpal, S. Goyal, D. Wahi et al., "Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease, " Gene, vol. 570, no. 1, pp. 115-121, 2015.
-
(2015)
Gene
, vol.570
, Issue.1
, pp. 115-121
-
-
Nagpal, N.1
Goyal, S.2
Wahi, D.3
-
152
-
-
84932620949
-
Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin
-
S. Larrat, S. Vallet, S. David-Tchouda et al., "Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin, " Journal of Clinical Microbiology, vol. 53, no. 7, pp. 2195-2202, 2015.
-
(2015)
Journal of Clinical Microbiology
, vol.53
, Issue.7
, pp. 2195-2202
-
-
Larrat, S.1
Vallet, S.2
David-Tchouda, S.3
-
153
-
-
84946490901
-
Predominance of hepatitis C virus Q80K among NS3 baseline-resistanceassociated amino acid variants in direct-antiviral-agent-nä?ve patients with chronic hepatitis: Single-centre experience
-
T. Ruggiero, A. Proietti, L. Boglione et al., "Predominance of hepatitis C virus Q80K among NS3 baseline-resistanceassociated amino acid variants in direct-antiviral-agent-nä?ve patients with chronic hepatitis: single-centre experience, " Archives of Virology, vol. 160, no. 11, pp. 2881-2885, 2015.
-
(2015)
Archives of Virology
, vol.160
, Issue.11
, pp. 2881-2885
-
-
Ruggiero, T.1
Proietti, A.2
Boglione, L.3
-
154
-
-
84890289271
-
Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-nä?ve patients
-
S. Paolucci, L. Fiorina, B. Mariani et al., "Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-nä?ve patients, " Virology Journal, vol. 10, article 355, 2013.
-
(2013)
Virology Journal
, vol.10
-
-
Paolucci, S.1
Fiorina, L.2
Mariani, B.3
-
155
-
-
84863663083
-
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
-
V. Cento, C. Mirabelli, R. Salpini et al., "HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors, " PLoS ONE, vol. 7, article e39652, 2012.
-
(2012)
PLoS ONE
, vol.7
-
-
Cento, V.1
Mirabelli, C.2
Salpini, R.3
-
156
-
-
84923842585
-
Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir +/? RBV
-
C. Sarrazin, H. Dvory-Sobol, E. S. Svarovskaia et al., "Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir +/? RBV, " Hepatology, vol. 60, no. 1, p. 1128a, 2014.
-
(2014)
Hepatology
, vol.60
, Issue.1
, pp. 1128a
-
-
Sarrazin, C.1
Dvory-Sobol, H.2
Svarovskaia, E.S.3
-
157
-
-
84923842285
-
Evaluation of the resistance profile of ledipasvir, a nonstructural protein 5A inhibitor, in genotype 1 chronically infected HCV subjects treated with ledipasvircontaining regimens without sofosbuvir
-
K. M. Kitrinos, D. Wyles, H. Dvory-Sobol, A. Worth, B. Han, and D. Brainard, "Evaluation of the resistance profile of ledipasvir, a nonstructural protein 5A inhibitor, in genotype 1 chronically infected HCV subjects treated with ledipasvircontaining regimens without sofosbuvir, " Hepatology, vol. 60, pp. 1143a-1144a, 2014.
-
(2014)
Hepatology
, vol.60
, pp. 1143a-1144a
-
-
Kitrinos, K.M.1
Wyles, D.2
Dvory-Sobol, H.3
Worth, A.4
Han, B.5
Brainard, D.6
-
158
-
-
84858415895
-
Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor
-
Z. Plaza, V. Soriano, E. Vispo et al., "Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor, " AntiviralTherapy, vol. 17, no. 5, pp. 921-926, 2012.
-
(2012)
AntiviralTherapy
, vol.17
, Issue.5
, pp. 921-926
-
-
Plaza, Z.1
Soriano, V.2
Vispo, E.3
-
159
-
-
84946207144
-
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir
-
R. Liu, S. Curry, P. McMonagle et al., "Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir, "AntimicrobialAgents and Chemotherapy, vol. 59, no. 11, pp. 6922-6929, 2015.
-
(2015)
AntimicrobialAgents and Chemotherapy
, vol.59
, Issue.11
, pp. 6922-6929
-
-
Liu, R.1
Curry, S.2
McMonagle, P.3
-
160
-
-
84961575132
-
Directly acting antivirals against hepatitis C virus: Mechanisms of action and impact of resistant associated variants
-
C. Premoli and A. Aghemo, "Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants, " Minerva Gastroenterologica e Dietologica, vol. 62, no. 1, pp. 76-87, 2016.
-
(2016)
Minerva Gastroenterologica e Dietologica
, vol.62
, Issue.1
, pp. 76-87
-
-
Premoli, C.1
Aghemo, A.2
-
161
-
-
82455192239
-
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations
-
R. A. Fridell, C. Wang, J.-H. Sun et al., "Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations, " Hepatology, vol. 54, no. 6, pp. 1924-1935, 2011.
-
(2011)
Hepatology
, vol.54
, Issue.6
, pp. 1924-1935
-
-
Fridell, R.A.1
Wang, C.2
Sun, J.-H.3
-
162
-
-
84862684876
-
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
-
E. J. Lawitz, D. Gruener, J. M. Hill et al., "A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C, " Journal of Hepatology, vol. 57, no. 1, pp. 24-31, 2012.
-
(2012)
Journal of Hepatology
, vol.57
, Issue.1
, pp. 24-31
-
-
Lawitz, E.J.1
Gruener, D.2
Hill, J.M.3
-
163
-
-
84941925149
-
Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: Significance for direct-acting antiviral treatment and drug resistance
-
L. Cuypers, G. Li, P. Libin, S. Piampongsant, A.-M. Vandamme, and K. Theys, "Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: significance for direct-acting antiviral treatment and drug resistance, " Viruses, vol. 7, no. 9, pp. 5018-5039, 2015.
-
(2015)
Viruses
, vol.7
, Issue.9
, pp. 5018-5039
-
-
Cuypers, L.1
Li, G.2
Libin, P.3
Piampongsant, S.4
Vandamme, A.-M.5
Theys, K.6
-
164
-
-
84896460675
-
Hepatitis C virus NS5A inhibitors and drug resistance mutations
-
S. Nakamoto, T. Kanda, S. Wu, H. Shirasawa, and O. Yokosuka, "Hepatitis C virus NS5A inhibitors and drug resistance mutations, " World Journal of Gastroenterology, vol. 20, no. 11, pp. 2902-2912, 2014.
-
(2014)
World Journal of Gastroenterology
, vol.20
, Issue.11
, pp. 2902-2912
-
-
Nakamoto, S.1
Kanda, T.2
Wu, S.3
Shirasawa, H.4
Yokosuka, O.5
-
165
-
-
84927926524
-
Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials
-
P. Krishnan, R. Tripathi, G. Schnell, T. Reisch, J. Beyer, and M. Irvin, "Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials, " Hepatology, vol. 60, no. 1, pp. 1134a-1135a, 2014.
-
(2014)
Hepatology
, vol.60
, Issue.1
, pp. 1134a-1135a
-
-
Krishnan, P.1
Tripathi, R.2
Schnell, G.3
Reisch, T.4
Beyer, J.5
Irvin, M.6
-
166
-
-
84863156581
-
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A
-
C. Wang, L. Jia, H. Huang et al., "In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A, " Antimicrobial Agents and Chemotherapy, vol. 56, no. 3, pp. 1588-1590, 2012.
-
(2012)
Antimicrobial Agents and Chemotherapy
, vol.56
, Issue.3
, pp. 1588-1590
-
-
Wang, C.1
Jia, L.2
Huang, H.3
-
167
-
-
84875804486
-
Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
-
D. Hernandez, N. Zhou, J. Ueland, A. Monikowski, and F. McPhee, "Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors, " Journal of Clinical Virology, vol. 57, no. 1, pp. 13-18, 2013.
-
(2013)
Journal of Clinical Virology
, vol.57
, Issue.1
, pp. 13-18
-
-
Hernandez, D.1
Zhou, N.2
Ueland, J.3
Monikowski, A.4
McPhee, F.5
-
168
-
-
84862560600
-
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir
-
F. McPhee, J. Friborg, S. Levine et al., "Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir, " AntimicrobialAgents and Chemotherapy, vol. 56, no. 7, pp. 3670-3681, 2012.
-
(2012)
AntimicrobialAgents and Chemotherapy
, vol.56
, Issue.7
, pp. 3670-3681
-
-
McPhee, F.1
Friborg, J.2
Levine, S.3
-
169
-
-
84880931245
-
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
-
Y. Karino, J. Toyota, K. Ikeda et al., "Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir, " Journal of Hepatology, vol. 58, no. 4, pp. 646-654, 2013.
-
(2013)
Journal of Hepatology
, vol.58
, Issue.4
, pp. 646-654
-
-
Karino, Y.1
Toyota, J.2
Ikeda, K.3
-
170
-
-
84924241449
-
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b
-
F. McPhee, D. Hernandez, N. Zhou et al., "Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b, " Antiviral Therapy, vol. 19, no. 5, pp. 479-490, 2014.
-
(2014)
Antiviral Therapy
, vol.19
, Issue.5
, pp. 479-490
-
-
McPhee, F.1
Hernandez, D.2
Zhou, N.3
-
171
-
-
84939174987
-
Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferonbased therapy
-
J. Itakura, M. Kurosaki, H. Takada et al., "Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferonbased therapy, " Hepatology Research, vol. 45, no. 10, pp. E115-E121, 2015.
-
(2015)
Hepatology Research
, vol.45
, Issue.10
, pp. E115-E121
-
-
Itakura, J.1
Kurosaki, M.2
Takada, H.3
-
172
-
-
84946488527
-
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice
-
Y. Kai, H. Hikita, T. Tatsumi et al., "Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice, " Journal of Gastroenterology, vol. 50, no. 11, pp. 1145-1151, 2015.
-
(2015)
Journal of Gastroenterology
, vol.50
, Issue.11
, pp. 1145-1151
-
-
Kai, Y.1
Hikita, H.2
Tatsumi, T.3
-
173
-
-
84906087908
-
Comparison of daclatasvir resistance barriers on NS5A fromhepatitisCvirus genotypes 1 to 6: Implications for cross-genotype activity
-
C. Wang, L. Jia, D. R. O'Boyle II et al., "Comparison of daclatasvir resistance barriers on NS5A fromhepatitisCvirus genotypes 1 to 6: Implications for cross-genotype activity, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 9, pp. 5155-5163, 2014.
-
(2014)
Antimicrobial Agents and Chemotherapy
, vol.58
, Issue.9
, pp. 5155-5163
-
-
Wang, C.1
Jia, L.2
O'Boyle, D.R.3
-
174
-
-
84961742925
-
Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden
-
I. Lindström, M. Kjellin, N. Palanisamy et al., "Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden, " InfectiousDiseases, vol. 47, no. 8, pp. 555-562, 2015.
-
(2015)
InfectiousDiseases
, vol.47
, Issue.8
, pp. 555-562
-
-
Lindström, I.1
Kjellin, M.2
Palanisamy, N.3
-
175
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
F. Poordad, C. Hezode, R. Trinh et al., "ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis, " The New England Journal ofMedicine, vol. 370, no. 21, pp. 1973-1982, 2014.
-
(2014)
The New England Journal OfMedicine
, vol.370
, Issue.21
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
-
176
-
-
84921276609
-
Infrequent development of resistance in genotype 1-6 hepatitis c virusinfected subjects treated with sofosbuvir in phase 2 and 3 clinical trials
-
E. S. Svarovskaia, H. Dvory Sobol, N. Parkin et al., "Infrequent development of resistance in genotype 1-6 hepatitis c virusinfected subjects treated with sofosbuvir in phase 2 and 3 clinical trials, " Clinical Infectious Diseases, vol. 59, no. 12, pp. 1666-1674, 2014.
-
(2014)
Clinical Infectious Diseases
, vol.59
, Issue.12
, pp. 1666-1674
-
-
Svarovskaia, E.S.1
Dvory Sobol, H.2
Parkin, N.3
-
177
-
-
84900992889
-
Sofosbuvir and ribavirin in HCV genotypes 2 and 3
-
S. Zeuzem, G. M. Dusheiko, R. Salupere et al., "Sofosbuvir and ribavirin in HCV genotypes 2 and 3, "The New England Journal of Medicine, vol. 370, no. 21, pp. 1993-2001, 2014.
-
(2014)
The New England Journal of Medicine
, vol.370
, Issue.21
, pp. 1993-2001
-
-
Zeuzem, S.1
Dusheiko, G.M.2
Salupere, R.3
-
178
-
-
84922879130
-
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation
-
M. Charlton, E. Gane, M. P. Manns et al., "Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation, "Gastroenterology, vol. 148, no. 1, pp. 108-117, 2015.
-
(2015)
Gastroenterology
, vol.148
, Issue.1
, pp. 108-117
-
-
Charlton, M.1
Gane, E.2
Manns, M.P.3
-
179
-
-
84894271490
-
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir
-
X. Tong, S. Le Pogam, L. Li et al., "In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir, " Journal of Infectious Diseases, vol. 209, no. 5, pp. 668-675, 2014.
-
(2014)
Journal of Infectious Diseases
, vol.209
, Issue.5
, pp. 668-675
-
-
Tong, X.1
Le Pogam, S.2
Li, L.3
-
180
-
-
84957687447
-
Simeprevir and sofosbuvir for treatment of hepatitis C infection
-
S. Chopp, R. Vanderwall, A. Hult, andM. Klepser, "Simeprevir and sofosbuvir for treatment of hepatitis C infection, " American Journal of Health-System Pharmacy, vol. 72, no. 17, pp. 1445-1455, 2015.
-
(2015)
American Journal of Health-System Pharmacy
, vol.72
, Issue.17
, pp. 1445-1455
-
-
Chopp, S.1
Vanderwall, R.2
Hult, A.3
Klepser, M.4
-
181
-
-
84898645159
-
Hepatitis c virus genetic variability and the presence of ns5b resistance-Associated mutations as natural polymorphisms in selected genotypes could affect the response to ns5b inhibitors
-
V. C. Di Maio, V. Cento, C. Mirabelli et al., "Hepatitis c virus genetic variability and the presence of ns5b resistance-Associated mutations as natural polymorphisms in selected genotypes could affect the response to ns5b inhibitors, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 5, pp. 2781-2797, 2014.
-
(2014)
Antimicrobial Agents and Chemotherapy
, vol.58
, Issue.5
, pp. 2781-2797
-
-
Di Maio, V.C.1
Cento, V.2
Mirabelli, C.3
-
182
-
-
84913539309
-
P1230 lack of impact of baseline resistance-associated variants (RAVS) on treatment outcome in the aviator study with ABT-450/R, ABT-333 and ABT-267, +/-Ribavirin
-
P. Krishnan, R. Tripathi, M. Irvin et al., "P1230 lack of impact of baseline resistance-associated variants (RAVS) on treatment outcome in the aviator study with ABT-450/R, ABT-333 AND ABT-267, +/-Ribavirin, " Journal of Hepatology, vol. 60, no. 1, article S498, 2014.
-
(2014)
Journal of Hepatology
, vol.60
, Issue.1
-
-
Krishnan, P.1
Tripathi, R.2
Irvin, M.3
|